Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer

Thyroid Cancer Research Laboratory, Endocrine Surgery Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Endocrinology (Impact Factor: 4.64). 12/2011; 153(2):985-94. DOI: 10.1210/en.2011-1519
Source: PubMed

ABSTRACT Human anaplastic thyroid cancer (ATC) is a lethal disease with an advanced clinical presentation and median survival of 3 months. The BRAF(V600E) oncoprotein is a potent transforming factor that causes human thyroid cancer cell progression in vitro and in vivo; therefore, we sought to target this oncoprotein in a late intervention model of ATC in vivo. We used the human ATC cell line 8505c, which harbors the BRAF(V600E) and TP53(R248G) mutations. Immunocompromised mice were randomized to receive the selective anti-BRAF(V600E) inhibitor, PLX4720, or vehicle by oral gavage 28 d after tumor implantation, 1 wk before all animals typically die due to widespread metastatic lung disease and neck compressive symptoms in this model. Mice were euthanized weekly to evaluate tumor volume and metastases. Control mice showed progressive tumor growth and lung metastases by 35 d after tumor implantation. At that time, all control mice had large tumors, were cachectic, and were euthanized due to their tumor-related weight loss. PLX4720-treated mice, however, showed a significant decrease in tumor volume and lung metastases in addition to a reversal of tumor-related weight loss. Mouse survival was extended to 49 d in PLX4720-treated animals. PLX4720 treatment inhibited cell cycle progression from 28 d to 49 d in vivo. PLX4720 induces striking tumor regression and reversal of cachexia in an in vivo model of advanced thyroid cancer that harbors the BRAF(V600E) mutation.

Download full-text


Available from: Sareh Parangi, Apr 21, 2015
  • Source
    • "It was shown that the tumors developing in this animal model undergo the glycolytic shift known as Warburg effect and are highly sensitive to the therapeutic use of glycolytic inhibitors, which synergize with standard chemotherapy [77]. Later, Nehs et al. [78] elegantly demonstrated the remarkable efficacy of PLX4720 compound, which is an ATP analog that selectively inhibits B-Raf V600E by stabilizing it in an inactive conformation [79] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human cancers. Actually, ATC is refractory to conventional therapies, including surgery, chemotherapy, radiotherapy, and radioiodine ((131)I) therapy. Accordingly, genetic and molecular characterizations of ATC have been frequently and periodically reviewed in order to identify potential biological markers exploitable for target therapy. This review briefly focuses on main molecular events that characterize ATC and provides an update about preclinical studies. In addition, the overexpression of transferrin receptor 1 (TfR1/CD71) by neoplastic cells of ATC is emphasized in that it could represent a potential therapeutic target. In this regard, new therapeutic approaches based on the use of monoclonal or recombinant antibodies, or transferrin-gallium-TfR1/CD71 molecular complexes, or lastly small interfering RNAs (siRNAs) are proposed.
    International Journal of Endocrinology 07/2014; 2014:685396. DOI:10.1155/2014/685396 · 1.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Anaplastic thyroid carcinoma (ATC) is a rare malignancy accounting for approxi-mately 2% of all thyroid cancers and has a median survival of less than 6 months [1]. The management options for patients with ATC are dependent upon the initial stage of presentation. It is unfortunate that the majority of patients present with clinical features consistent with extrathyroidal dis-ease at the time of their initial presentation [2]. This has a significant impact on the capacity for local control and the ability for complete surgical resection. The cause of death in most patients with ATC is asphyxiation due to direct tumor extension. The peak incidence of diagnosis occurs in the sixth and seventh decades of life. Unfortunately, comorbidities more fre-quently encountered in this age group may limit the ability of an individual patient to tolerate the toxicity associated with aggressive treatment protocols. The typical presenting complaint of a patient with ATC is with regard to an enlarging neck mass. Delays inherent to the routine assessment of these patients can be difficult to control and have the capacity to impact survival. The timeline from the onset of symptoms to initial evaluation, subsequent surgical consul-tation, initial diagnostic biopsy, imag-ing and scheduling for definitive surgical resection can easily extend to 4 weeks. Patients presenting for evaluation of acute airway obstruction may complete this assessment in a more expeditious manner; however, their symptoms may also reflect unresectable disease. The increased use of ultrasound in the office setting offers the potential for early identification of thyroid malignancies in the asymptomatic patient. The recent modifications of the American Thyroid Association guidelines advocating fine needle aspiration of nodules ≥5 mm with suspicious features also facilitates earlier diagnosis of lesions that require surgical intervention [3].
    Expert Review of Endocrinology &amp Metabolism 07/2012; 7(5):483-5. DOI:10.1586/eem.12.46
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Papillary thyroid cancer (PTC) recurrence risk is difficult to predict. No current risk classification system incorporates BRAF mutational status. Here, we assess the incremental value of BRAF mutational status in predicting PTC recurrence relative to existing recurrence risk algorithms. Serial data were collected for a historical cohort having undergone total thyroidectomy for papillary thyroid carcinoma (PTC) during a 5-year period. Corresponding BRAF(V600E) testing was performed and Cox proportional hazard regression modeling, with and without BRAF status, was used to evaluate existing recurrence risk algorithms. The 5-year cumulative PTC recurrence incidence within our 356 patient cohort was 15%. A total of 205 (81%) of associated archived specimens were successfully genotyped, and 110 (54%) harbored the BRAF(V600E) mutation. The 5-year cumulative recurrence incidence among BRAF(V600E) patients was 20% versus 8% among BRAF wild type. BRAF(V600E) was significantly associated with time to recurrence when added to the following algorithms: AMES (hazard ratio [HR] 2.43 [confidence interval 1.08-5.49]), MACIS category (HR 2.46 [1.09-5.54]), AJCC-TNM (HR 2.51 [1.11-5.66]), and ATA recurrence-risk category (HR 2.44 [1.08-5.50]), and model discrimination improved (incremental c-index range 0.046-0.109). The addition of BRAF mutational status to established risk algorithms improves the discrimination of risk recurrence in patients undergoing total thyroidectomy for PTC.
    Surgery 12/2012; 152(6):984-90. DOI:10.1016/j.surg.2012.08.039 · 3.11 Impact Factor
Show more